Effects of Beraprost with or without NOS Inhibition on Plasma Aldosterone and Hemodynamics in Healthy Cats

Abstract

Objectives: The aim of the study was to evaluate the hemodynamic and RA system effects of the oral administration of the clinical dose of beraprost for feline CKD in healthy cats, and also to examine whether NOS inhibition reversed them. Methods: A placebo-controlled pharmacological sequential design study was carried out to assess the plasma aldosterone and renin concentrations (PAC and PRC), blood pressure, heart rate, and exploratorily to estimate renal plasma flow (RPF) and renal vascular resistance (RVR) with simplified methods. Results: Beraprost reduced PAC when compared to the placebo (p p 2) showed opposite relationships between beraprost and the added L-NAME effects on PAC, mean blood pressure (MBP), heart rate, estimated RPF (p p p < 0.05). Conclusions: In healthy cats, the clinical dose of beraprost suppresses PAC, which can be reversed by the inhibition of NOS.

Keywords

• beraprost
• feline
• chronic kidney disease
• aldosterone
• NOS